Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 254

1.

Positron Emission Tomography Scanning for Recurrent Bladder Cancer.

Wilson JM, Huddart RA.

Eur Urol Focus. 2016 Jun;2(2):219-220. doi: 10.1016/j.euf.2016.02.002. Epub 2016 Mar 19.

PMID:
28723538
2.

Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer.

Patrikidou A, Uccello M, Tree A, Parker C, Attard G, Eeles R, Khoo V, van As N, Huddart R, Dearnaley D, Reid A.

Clin Oncol (R Coll Radiol). 2017 Jun 23. pii: S0936-6555(17)30281-9. doi: 10.1016/j.clon.2017.06.006. [Epub ahead of print] No abstract available.

PMID:
28652092
3.

Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.

Litchfield K, Levy M, Orlando G, Loveday C, Law PJ, Migliorini G, Holroyd A, Broderick P, Karlsson R, Haugen TB, Kristiansen W, Nsengimana J, Fenwick K, Assiotis I, Kote-Jarai Z, Dunning AM, Muir K, Peto J, Eeles R, Easton DF, Dudakia D, Orr N, Pashayan N; UK Testicular Cancer Collaboration; PRACTICAL Consortium, Bishop DT, Reid A, Huddart RA, Shipley J, Grotmol T, Wiklund F, Houlston RS, Turnbull C.

Nat Genet. 2017 Jul;49(7):1133-1140. doi: 10.1038/ng.3896. Epub 2017 Jun 12.

PMID:
28604728
4.

Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.

Hafeez S, McDonald F, Lalondrelle S, McNair H, Warren-Oseni K, Jones K, Harris V, Taylor H, Khoo V, Thomas K, Hansen V, Dearnaley D, Horwich A, Huddart R.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):115-122. doi: 10.1016/j.ijrobp.2017.01.239. Epub 2017 Feb 9.

5.

Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.

Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, Kelly JD, Kirkbank T, McLaren DB, Mead G, Moynihan C, Persad R, Scrase C, Lewis R, Hall E.

BJU Int. 2017 Apr 28. doi: 10.1111/bju.13900. [Epub ahead of print]

PMID:
28453896
6.

R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.

Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, Mook S, Sahgal A, Hall E, Schultz C.

Front Oncol. 2017 Apr 3;7:59. doi: 10.3389/fonc.2017.00059. eCollection 2017.

7.

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A, Sundar S, Crabb SJ, Dixon-Hughes J, Alexander L, Morris A, Kelly C, Stobo J, Paul J, Powles T.

J Clin Oncol. 2017 Jun 1;35(16):1770-1777. doi: 10.1200/JCO.2016.70.7828. Epub 2017 Apr 12.

PMID:
28402747
8.

A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).

Shamash J, Sarker SJ, Huddart R, Harland S, Joffe JK, Mazhar D, Birtle A, White J, Chowdhury K, Wilson P, Marshall MR, Vinnicombe S.

Ann Oncol. 2017 Jun 1;28(6):1333-1338. doi: 10.1093/annonc/mdx071.

PMID:
28327896
9.

The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?

Trainor S, Choudhury A, Huddart R, Kiltie AE, Kockelbergh R, Turner W, Birtle A, Crabb SJ.

Clin Oncol (R Coll Radiol). 2017 Jun;29(6):344-347. doi: 10.1016/j.clon.2017.01.040. Epub 2017 Feb 9. No abstract available.

PMID:
28190637
10.

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).

Choudhury A, West CM, Porta N, Hall E, Denley H, Hendron C, Lewis R, Hussain SA, Huddart R, James N.

Br J Cancer. 2017 Feb 28;116(5):649-657. doi: 10.1038/bjc.2017.2. Epub 2017 Jan 26.

PMID:
28125821
11.

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.

Hussain SA, Ansari J, Huddart R, Power DG, Lyons J, Wylie J, Vilarino-Varlela M, Elander NO, McMenemin R, Pickering LM, Faust G, Chauhan S, Jackson RJ.

Int J Oncol. 2017 Mar;50(3):768-772. doi: 10.3892/ijo.2017.3847. Epub 2017 Jan 13.

12.

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S, Chester J, Hilman S, Beresford M, Macdonald G, Santhanam S, Frew JA, Stockdale A, Hughes S, Berney D, Chowdhury S.

J Clin Oncol. 2017 Jan;35(1):48-55. Epub 2016 Oct 28.

PMID:
28034079
13.

Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility.

Litchfield K, Levy M, Dudakia D, Proszek P, Shipley C, Basten S, Rapley E, Bishop DT, Reid A, Huddart R, Broderick P, Castro DG, O'Connor S, Giles RH, Houlston RS, Turnbull C.

Nat Commun. 2016 Dec 20;7:13840. doi: 10.1038/ncomms13840.

14.

The present and future of serum diagnostic tests for testicular germ cell tumours.

Murray MJ, Huddart RA, Coleman N.

Nat Rev Urol. 2016 Dec;13(12):715-725. doi: 10.1038/nrurol.2016.170. Epub 2016 Oct 18. Review.

PMID:
27754472
15.

The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.

Pathmanathan AU, Alexander EJ, Huddart RA, Tree AC.

Future Oncol. 2016 Nov;12(21):2495-2511. Epub 2016 Jun 20. Review.

PMID:
27322113
16.

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M.

J Clin Oncol. 2016 Aug 1;34(22):2636-43. doi: 10.1200/JCO.2016.66.9697. Epub 2016 Jun 13.

PMID:
27298414
17.

The genomic landscape of testicular germ cell tumours: from susceptibility to treatment.

Litchfield K, Levy M, Huddart RA, Shipley J, Turnbull C.

Nat Rev Urol. 2016 Jul;13(7):409-19. doi: 10.1038/nrurol.2016.107. Epub 2016 Jun 14. Review.

PMID:
27296647
18.

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.

Hafeez S, Horwich A, Omar O, Mohammed K, Thompson A, Kumar P, Khoo V, Van As N, Eeles R, Dearnaley D, Huddart R.

Br J Cancer. 2016 Jun 14;114(12):e24. doi: 10.1038/bjc.2016.132. Epub 2016 May 26. No abstract available.

19.

Polygenic susceptibility to testicular cancer: implications for personalised health care.

Litchfield K, Mitchell JS, Shipley J, Huddart R, Rajpert-De Meyts E, Skakkebæk NE, Houlston RS, Turnbull C.

Br J Cancer. 2016 Jun 14;114(12):e22. doi: 10.1038/bjc.2016.136. Epub 2016 May 26. No abstract available.

20.

Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.

Hafeez S, Warren-Oseni K, McNair HA, Hansen VN, Jones K, Tan M, Khan A, Harris V, McDonald F, Lalondrelle S, Mohammed K, Thomas K, Thompson A, Kumar P, Dearnaley D, Horwich A, Huddart R.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1022-30. doi: 10.1016/j.ijrobp.2015.12.379. Epub 2016 Jan 6.

Supplemental Content

Loading ...
Support Center